Stocks · News reference
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings of 23 cents per share and sales of $20.898 million. Other stocks gaining pre-market include DarkIris Inc (NASDAQ:DKI), Jin Medical International Ltd (NASDAQ:ZJYL), and Volato Group Inc (NYSE:SOAR).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barnes & Noble, Carter's, Kohl's Join DoorDash Marketplace
Between new class schedules, sports practices, and the scramble to find the right size backpack and outfits, back-to-school season is one of the busiest shopping moments of the year and one of the most time-consuming.
12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
Gainers Fossil Group (NASDAQ:FOSL) stock rose 11.9% to $5.9 during Wednesday's after-market session. The market value of their outstanding shares is at $309.6 million. As per the press release, Q2 earnings came out
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Filed: 2026-08-31 AccNo: 0001477932-26-005329 Size: 947 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.